Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics

Abstract

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

1 - 219 . (canceled) 
     
     
         220 . A method of treatment of a cancer in a subject in need of treatment thereof, the method comprising administering an isolated antibody selected from the group consisting of:
 a monoclonal or polyclonal antibody comprising an antigen binding site that binds specifically to a polypeptide selected from a group consisting of the following (i)-(iii)   (i) a C1ORF32 ectodomain polypeptide comprising the amino acid sequence of SEQ ID NO:299,   (ii) a C1ORF32 ectodomain polypeptide comprising the amino acid sequence of SEQ ID NO:147,   (iii) a C1ORF32 ectodomain polypeptide comprising the amino acid sequence of SEQ ID NO:148,   and an antigen-binding fragment of the antibody selected from a group consisting of Fab, Fab′, F(ab′)2, F(ab′), F(ab), Fv and scFv;   wherein the cancer is selected from the group consisting of colon cancer, myeloma, stomach cancer, head and neck cancer, cancer of the cervix, kidney cancer, lung cancer, and bladder cancer.   
     
     
         221 . The method of  claim 220 , wherein said cancer is selected from the group consisting of colon cancer and myeloma. 
     
     
         222 . The method of  claim 220 , wherein the antibody or antibody-binding fragment of any of the above claims, wherein the antibody or the antibody-binding fragment is selected from a group consisting of a fully human antibody, chimeric antibody, humanized or primatized antibody; Fab, Fab′, F(ab′)2, F(ab′), F(ab), Fv and ScFv fragment thereof. 
     
     
         223 . The method of  claim 220 , wherein the antibody or the antibody-binding fragment is coupled to a moiety selected from a drug, radionuclide, fluorophore, an enzyme, a toxin, a therapeutic agent, a chemotherapeutic agent or a detectable marker, and wherein the detectable marker is radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound. 
     
     
         224 . The method of  claim 220 , wherein the cancer is selected from the group consisting of non-metastatic, invasive and metastatic forms. 
     
     
         225 . The method of  claim 220 , wherein the antigen binding site contains binds to at least 3-7 contiguous or non-contiguous amino acids. 
     
     
         226 . The method of  claim 225 , wherein the antigen binding site binds to a conformational or linear epitope containing 5-7 amino acids. 
     
     
         227 . The method of  claim 220 , wherein the cancer is a malignancy that expresses the protein of SEQ ID NO:50. 
     
     
         228 . The method of  claim 220 , further comprising co-administering a chemotherapeutic agent. 
     
     
         229 . The method of  claim 220 , wherein said chemotherapeutic agent is selected from the group consisting of taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, antimetabolites, alkylating agents, anthracyclines, antibiotics, anti-mitotic agents, duocarmycins, calicheamicins, maytansines and auristatins. 
     
     
         230 . The method of  claim 220 , wherein said chemotherapeutic agent is selected from the group consisting of daunorubicin, doxorubicin, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine, vincristine, vinblastine, dactinomycin, bleomycin, mithramycin, anthramycin AMC, mechlorethamine, thioepa chlorambucil, melphalan, carmustine, BSNU, lomustine CCNU, cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, cis-dichlorodiamine platinum II, DDP and cisplatin. 
     
     
         231 . The method of  claim 220 , wherein the antibody is administered in a pharmaceutically acceptable diluent or carrier.